2,439 Stryker Corporation $SYK Shares Sold by Baskin Financial Services Inc.

Baskin Financial Services Inc. reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 110,407 shares of the medical technology company’s stock after selling 2,439 shares during the quarter. Stryker makes up approximately 2.5% of Baskin Financial Services Inc.’s holdings, making the stock its 21st biggest position. Baskin Financial Services Inc.’s holdings in Stryker were worth $30,405,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in SYK. Bank of America Corp DE acquired a new position in Stryker during the second quarter worth $1,404,284,000. Legal & General Group Plc acquired a new stake in Stryker in the 2nd quarter valued at $707,212,000. Jupiter Topco LLC bought a new stake in Stryker during the 2nd quarter worth about $681,581,000. Corient Private Wealth LP bought a new stake in Stryker during the 2nd quarter worth about $323,035,000. Finally, Flossbach Von Storch SE acquired a new position in shares of Stryker during the 2nd quarter worth about $464,506,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of SYK stock traded up $3.94 on Monday, reaching $298.60. The stock had a trading volume of 1,218,776 shares, compared to its average volume of 2,443,594. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm’s 50-day moving average is $299.31 and its two-hundred day moving average is $312.76. The firm has a market capitalization of $114.54 billion, a price-to-earnings ratio of 30.96, a P/E/G ratio of 1.87 and a beta of 0.78. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $392.55.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Truist Financial decreased their price objective on Stryker from $340.00 to $310.00 and set a “hold” rating for the company in a report on Tuesday, October 6th. TD Cowen dropped their target price on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a report on Tuesday, September 22nd. Wells Fargo & Company reduced their price target on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. Barclays upgraded Stryker to a “strong-buy” rating in a research note on Wednesday, October 7th. Finally, Citigroup decreased their price target on Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $369.00.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.